137 related articles for article (PubMed ID: 33823101)
21. Randomised controlled trial evaluating the effectiveness and cost-effectiveness of 'Families for Health', a family-based childhood obesity treatment intervention delivered in a community setting for ages 6 to 11 years.
Robertson W; Fleming J; Kamal A; Hamborg T; Khan KA; Griffiths F; Stewart-Brown S; Stallard N; Petrou S; Simkiss D; Harrison E; Kim SW; Thorogood M
Health Technol Assess; 2017 Jan; 21(1):1-180. PubMed ID: 28059054
[TBL] [Abstract][Full Text] [Related]
22. Lifestyle intervention for improving school achievement in overweight or obese children and adolescents.
Martin A; Saunders DH; Shenkin SD; Sproule J
Cochrane Database Syst Rev; 2014 Mar; (3):CD009728. PubMed ID: 24627300
[TBL] [Abstract][Full Text] [Related]
23. Improvements in health-related quality of life with liraglutide 3.0 mg compared with placebo in weight management.
Kolotkin RL; Fujioka K; Wolden ML; Brett JH; Bjorner JB
Clin Obes; 2016 Aug; 6(4):233-42. PubMed ID: 27198973
[TBL] [Abstract][Full Text] [Related]
24. Effects of lifestyle intervention and metformin on weight management and markers of metabolic syndrome in obese adolescents.
Harden KA; Cowan PA; Velasquez-Mieyer P; Patton SB
J Am Acad Nurse Pract; 2007 Jul; 19(7):368-77. PubMed ID: 17680902
[TBL] [Abstract][Full Text] [Related]
25. Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Prevented Weight Regain in Obese Women with Polycystic Ovary Syndrome Previously Treated with Liraglutide: A Pilot Randomized Study.
Ferjan S; Janez A; Jensterle M
Metab Syndr Relat Disord; 2017 Dec; 15(10):515-520. PubMed ID: 29064743
[TBL] [Abstract][Full Text] [Related]
26. The safety of pharmacologic treatment for pediatric obesity.
Chao AM; Wadden TA; Berkowitz RI
Expert Opin Drug Saf; 2018 Apr; 17(4):379-385. PubMed ID: 29411652
[TBL] [Abstract][Full Text] [Related]
27. The Effect of a Multidisciplinary Lifestyle Intervention on Obesity Status, Body Composition, Physical Fitness, and Cardiometabolic Risk Markers in Children and Adolescents with Obesity.
Seo YG; Lim H; Kim Y; Ju YS; Lee HJ; Jang HB; Park SI; Park KH
Nutrients; 2019 Jan; 11(1):. PubMed ID: 30634657
[TBL] [Abstract][Full Text] [Related]
28. Effectiveness and cost of integrating a pragmatic pathway for prescribing liraglutide 3.0 mg in obesity services (STRIVE study): study protocol of an open-label, real-world, randomised, controlled trial.
Papamargaritis D; Al-Najim W; Lim J; Crane J; Lean M; le Roux C; McGowan B; O'Shea D; Webb D; Wilding J; Davies MJ
BMJ Open; 2020 Feb; 10(2):e034137. PubMed ID: 32060156
[TBL] [Abstract][Full Text] [Related]
29. The Current Role of Liraglutide in the Pharmacotherapy of Obesity.
Christou GA; Katsiki N; Kiortsis DN
Curr Vasc Pharmacol; 2016; 14(2):201-7. PubMed ID: 26074046
[TBL] [Abstract][Full Text] [Related]
30. The adolescent with obesity: what perspectives for treatment?
Nicolucci A; Maffeis C
Ital J Pediatr; 2022 Jan; 48(1):9. PubMed ID: 35033162
[TBL] [Abstract][Full Text] [Related]
31. Bariatric surgery in adolescents: a prospective randomized controlled trial comparing laparoscopic gastric banding to combined lifestyle interventions in adolescents with severe obesity (BASIC trial).
Roebroek YGM; Paulus GF; van Mil EGAH; Vreugdenhil ACE; Winkens B; Nederkoorn C; Stehouwer CDA; Greve JWM; Bouvy ND; van Heurn LWE
BMC Pediatr; 2019 Jan; 19(1):34. PubMed ID: 30691442
[TBL] [Abstract][Full Text] [Related]
32. A combined nutritional-behavioral-physical activity intervention for the treatment of childhood obesity--a 7-year summary.
Nemet D; Levi L; Pantanowitz M; Eliakim A
J Pediatr Endocrinol Metab; 2014 May; 27(5-6):445-51. PubMed ID: 24464474
[TBL] [Abstract][Full Text] [Related]
33. Effectiveness and tolerability of orlistat and liraglutide in patients with obesity in a real-world setting: The XENSOR Study.
Gorgojo-Martínez JJ; Basagoiti-Carreño B; Sanz-Velasco A; Serrano-Moreno C; Almodóvar-Ruiz F
Int J Clin Pract; 2019 Nov; 73(11):e13399. PubMed ID: 31397946
[TBL] [Abstract][Full Text] [Related]
34. [Pharmacotherapy for obesity].
Bruun JM
Ugeskr Laeger; 2016 Oct; 178(44):. PubMed ID: 27808050
[TBL] [Abstract][Full Text] [Related]
35. Exposure-response analyses of liraglutide 3.0 mg for weight management.
Wilding JP; Overgaard RV; Jacobsen LV; Jensen CB; le Roux CW
Diabetes Obes Metab; 2016 May; 18(5):491-9. PubMed ID: 26833744
[TBL] [Abstract][Full Text] [Related]
36. [Obesity treatment with liraglutide in a patient with Prader-Willi syndrome: a case report].
Cadena-Obando DA; Molina-Ayala MA; Ferreira-Hermosillo A
Nutr Hosp; 2018 May; 35(3):743-746. PubMed ID: 29974787
[TBL] [Abstract][Full Text] [Related]
37. Health-related quality of life and perceived health status of adolescents with obesity are improved by a 10-month multidisciplinary intervention.
Khammassi M; Miguet M; O'Malley G; Fillon A; Masurier J; Damaso AR; Pereira B; Lambert C; Duclos M; Courteix D; Boirie Y; Thivel D
Physiol Behav; 2019 Oct; 210():112549. PubMed ID: 31082444
[TBL] [Abstract][Full Text] [Related]
38. Inpatient treatment of children and adolescents with severe obesity in the Netherlands: a randomized clinical trial.
van der Baan-Slootweg O; Benninga MA; Beelen A; van der Palen J; Tamminga-Smeulders C; Tijssen JG; van Aalderen WM
JAMA Pediatr; 2014 Sep; 168(9):807-14. PubMed ID: 25022831
[TBL] [Abstract][Full Text] [Related]
39. Effect of class-based lifestyle intervention on the management of childhood obesity.
Pan HJ; Hung LJ; Chen CY
Obes Res Clin Pract; 2020; 14(2):184-190. PubMed ID: 32381350
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
